PharVision Advisers’s Microsoft MSFT Stock Holding History

PharVision Advisers’s Portfolio MSFT Stock Details MSFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-613	Closed	-$296K	–	443
2025 Q4	$296K	Sell	613 -110	-15%	-$55.1K	0.15%	279
2025 Q3	$374K	Buy	+723	New	+$369K	0.21%	105

Other funds holding MSFT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

PharVision Advisers's MSFT Position: Q1 2026 in Review

PharVision Advisers sold out of Microsoft (MSFT) in Q1 2026, closing a stake of 613 shares — an estimated $296K sold.

PharVision Advisers first reported a position in MSFT in Q3 2025 and held it in 2 quarters. The position peaked at $374K in Q3 2025. 6,181 funds tracked by Wall St. Rank hold MSFT as of Q1 2026.

PharVision Advisers reported no remaining Microsoft position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 613 Microsoft shares in Q1 2026, an estimated $296K.
PharVision Advisers first reported a position in Microsoft in Q3 2025 and held it in 2 quarters.
PharVision Advisers's Microsoft position peaked at $374K in Q3 2025.
6,181 funds tracked by Wall St. Rank held Microsoft as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.